Submit Deal

ADJUVANT CAPITAL

Summary

Adjuvant Capital is a life sciences investment firm focused on global health.

Deals Overview

Total Deals8

Valued Deals8

Total Value£ 378 M

Avg. Deal Size£ 47 M

Market Context

Senior Management

Glenn Rockman
‎Founder and Managing Partner
Charlie Petty
Co-Founder and Principal
Jenny Yip
Managing Partner

Sort

24 Feb 2021|China|Biotechnology

Target: YISHENG BIOPHARMA

Bidder: ADJUVANT CAPITAL

16 Service Providers

4 Target | 12 Bidder

12 Dealmakers

2 Target | 10 Bidder

£ 92 M

Value

17 Feb 2021|United States|Pharmaceuticals

Target: EXCISION BIOTHERAPEUTICS

Bidder: ANZU PARTNERS

11 Service Providers

2 Target | 9 Bidder

22 Dealmakers

8 Target | 14 Bidder

£ 43 M

Value

10 Feb 2022|United States|Biotechnology

Target: CUREVO VACCINE

Bidder: GC PHARMA

5 Service Providers

2 Target | 3 Bidder

5 Dealmakers

2 Target | 3 Bidder

£ 44 M

Value

19 Oct 2022|Belgium|Biotechnology

Target: UNIVERCELLS

Bidder: SFPI-FPIM

12 Service Providers

4 Target | 8 Bidder

14 Dealmakers

6 Target | 8 Bidder

£ 38 M

Value

15 Dec 2022|Denmark|Biotechnology

Target: MINERVAX

Bidder: TRILL IMPACT

4 Service Providers

2 Target | 2 Bidder

5 Dealmakers

3 Target | 2 Bidder

£ 61 M

Value

15 Feb 2023|United States|Biotechnology

Target: CODAGENIX

Bidder: SERUM INSTITUTE OF INDIA

7 Service Providers

4 Target | 3 Bidder

9 Dealmakers

6 Target | 3 Bidder

£ 20 M

Value

11 Oct 2023|Denmark|Biotechnology

Target: MINERVAX

Bidder: EQT LIFE SCIENCES

4 Service Providers

2 Target | 2 Bidder

5 Dealmakers

3 Target | 2 Bidder

£ 46 M

Value

09 Oct 2023|Switzerland|Biotechnology

Target: LIMMATECH BIOLOGICS

Bidder: ADJUVANT CAPITAL

3 Service Providers

1 Target | 2 Bidder

6 Dealmakers

1 Target | 5 Bidder

£ 30 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy